Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib-Based Therapy from ASH 2012
Trials
Relapsed: D + PD Treatment | DARZALEX® IV (daratumumab)
![PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/be4724496d6a2bc3c1ce363734069c2dc2a77f30/2-Figure1-1.png "PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar")
PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar
PDF) Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Daratumumab Re-Treatment Patterns. DPd: daratumumab, pomalidomide, and... | Download Scientific Diagram
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Car/Pom/Dex in RR MM - Slideset Download - Hematology 2016 | CCO
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Meta-analysis of the response rate of carfilzomib/pomalidomide single... | Download Scientific Diagram
Carfilzomib/Pomalidomide and Dexamethasone for Relapsed/Refractory MM | Research To Practice
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
Retrospective Study of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients in a Tertiary Care Hospital in India | SpringerLink
Carfilzomib/Pomalidomide and Dexamethasone for Relapsed/Refractory MM | Research To Practice
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
KPd - Multiple Myeloma Clinical Trials
D-KPd - Multiple Myeloma Clinical Trials
Understanding Freelite | Int'l Myeloma Fndtn
